As you might know, GSK plc (LON:GSK) recently reported its interim numbers. GSK reported UK£16b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of UK£0.35 beat expectations, being 3.5% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we’ve gathered the latest statutory forecasts to see what the analysts are expecting for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

LSE:GSK Earnings and Revenue Growth August 1st 2025

Taking into account the latest results, GSK’s 17 analysts currently expect revenues in 2025 to be UK£32.0b, approximately in line with the last 12 months. Per-share earnings are expected to shoot up 53% to UK£1.30. Yet prior to the latest earnings, the analysts had been anticipated revenues of UK£31.9b and earnings per share (EPS) of UK£1.41 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

Check out our latest analysis for GSK

The consensus price target held steady at UK£16.52, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. There’s another way to think about price targets though, and that’s to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values GSK at UK£25.10 per share, while the most bearish prices it at UK£11.20. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The analysts are definitely expecting GSK’s growth to accelerate, with the forecast 2.1% annualised growth to the end of 2025 ranking favourably alongside historical growth of 1.4% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 5.1% per year. It seems obvious that, while the future growth outlook is brighter than the recent past, GSK is expected to grow slower than the wider industry.